Bioventus

Update in progress

BVS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

Bioventus is a medical device company focused on pain relief and musculoskeletal therapies worldwide. Its portfolio includes intra-articular and hyaluronic acid injections (Durolane, GELSYN-3, SUPARTZ), peripheral nerve stimulation (Stimrouter, TalisMann) and the XCELL PRP System. It also offers ultrasonic and bone fusion tools (neXus, BoneScalpel, SonaStar, SonicOne) and bone grafts (Osteoamp, Reficio, Purebone, Signafuse). Exogen supports fracture healing. Founded 2011, Durham, NC.

Company score

Sentiment: 0.23; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.24; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.16; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive